328 related articles for article (PubMed ID: 30914334)
1. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
[TBL] [Abstract][Full Text] [Related]
2. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
[TBL] [Abstract][Full Text] [Related]
3. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
[TBL] [Abstract][Full Text] [Related]
4. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Csizmadi I; Freedland SJ
J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
[TBL] [Abstract][Full Text] [Related]
5. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ; Moreira DM
J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
[TBL] [Abstract][Full Text] [Related]
6. Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations.
Moreira DM; Andriole GL; Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ
World J Urol; 2017 Oct; 35(10):1525-1530. PubMed ID: 28396999
[TBL] [Abstract][Full Text] [Related]
7. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
8. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
9. Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy.
Kuang AG; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
BJU Int; 2019 Jan; 123(1):91-97. PubMed ID: 29873889
[TBL] [Abstract][Full Text] [Related]
10. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
11. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
13. Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Freedland SJ; Csizmadi I
Prostate; 2023 Jul; 83(10):990-997. PubMed ID: 37070723
[TBL] [Abstract][Full Text] [Related]
14. Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
Naha U; Nickel JC; Andriole GL; Freedland SJ; Moreira DM
J Urol; 2021 Mar; 205(3):755-760. PubMed ID: 33080149
[TBL] [Abstract][Full Text] [Related]
15. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
[TBL] [Abstract][Full Text] [Related]
17. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.
Moreira DM; de O Freitas DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):413-417. PubMed ID: 28585572
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
19. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.
Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate; 2015 Sep; 75(13):1492-8. PubMed ID: 26184556
[TBL] [Abstract][Full Text] [Related]
20. Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy.
Moreira DM; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):106-112. PubMed ID: 29203895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
